Sage Therapeutics (SAGE) : Thursdays money flow indicated an uptick to downtick ratio was at 1.67. The total value of inflow transactions on upticks was $1.27 million, whereas, the total value of outflow trades on downticks was $0.76 million. The total money flow was $0.51 million, which shows a mild bullish bias. The total money flow into the stock in block trades was $0.52 million. The total value of the trades done on upticks was $0.52 million. Sage Therapeutics (SAGE) was trading with a -1.33% change over previous days close. It fell $0.43 during the day and reached $31.89. The stock was 2.54% compared to the previous weeks close.
Sage Therapeutics (SAGE) stock is expected to deviate a maximum of $28.16 from the average target price of $67.86 for the short term period. 7 Street Experts have initiated coverage on the stock with the most promising target being $95 and the most muted being $18. The stock has recorded a 20-day Moving Average of 7.89% and the 50-Day Moving Average is 0.03%.
Sage Therapeutics (NASDAQ:SAGE): The stock opened at $32.52 on Thursday but the bulls could not build on the opening and the stock topped out at $33.01 for the day. The stock traded down to $31.15 during the day, due to lack of any buying support eventually closed down at $32.16 with a loss of -0.50% for the day. The stock had closed at $32.32 on the previous day. The total traded volume was 600,772 shares.
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat life-threatening, rare central nervous system (CNS) disorders. The Companys lead product candidate in its status epilepticus (SE) program is SAGE-547. SAGE-689 and SAGE-217 are two additional product candidates in its pipeline. The Company has submitted investigational new drug (IND) for SAGE-547 for the treatment of SRSE with the United States Food and Drug Administration. SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABAA receptors. SAGE-217 is a neuroactive steroid that acts as a positive allosteric modulator of synaptic and extra-synaptic GABAA receptor subtypes. SAGE-689 is being developed as an adjunctive IV therapy for the treatment of status epilepticus patients.